Ainos to Participate in Fireside Chat with Water Tower Research on August 20, 2025
Rhea-AI Summary
Ainos (NASDAQ:AIMD), a company specializing in AI-powered scent detection, has announced its participation in an upcoming fireside chat with Water Tower Research on August 20, 2025, at 11:00 a.m. ET.
During the chat, the company will discuss its AI Nose technology, recent strategic partnerships, and deployment progress. Management will also address market opportunities, upcoming milestones for 2025-2026, and position Ainos as a core technology company. The event will be available for replay on the company's investor relations website.
Positive
- None.
Negative
- None.
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent detection, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research, on Wednesday, August 20, 2025, at 11:00 a.m. ET.
Ainos will highlight the uniqueness of its AI Nose technology, underscoring recent strategic partnerships and the rapid acceleration of AI Nose deployment. In addition, the Company will also share insights into market and scale-up opportunities across multiple sectors, outline key milestones expected for the remainder of 2025 and into 2026, and make the case for why Ainos should be regarded as a technology company at its core.
To register for this listen-only event, please visit:
Fireside Chat Registration Link
The replay of the fireside chat will be available under "Events" on Ainos' investor relations website at https://ir.ainos.com/.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information:
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Ainos (AIMD) scheduled to participate in the Water Tower Research fireside chat?
What topics will be covered in the Ainos (AIMD) fireside chat?
How can investors access the Ainos (AIMD) fireside chat?
What is Ainos (AIMD) main technology focus?
